Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. - Wikidata - wikimedia - TriplyDB

Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.

Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.

http://www.wikidata.org/entity/Q42145566

about

Vaccines for preventing herpes zoster in older adults Understanding natural herpes simplex virus immunity to inform next-generation vaccine design Varicella Zoster Virus in the Nervous System Immune correlates of vaccine protection against HIV-1 acquisition Vaccination of healthcare workers: A review Local innate immune responses in the vaccine adjuvant-injected muscle Herpes zoster and postherpetic neuralgia in older adults Varicella Zoster Virus: A Common Cause of Stroke in Children and Adults Healthcare maintenance in elderly patients with inflammatory bowel disease.Herpes Zoster and Recurrent Herpes Zoster A case control study on family history as a risk factor for herpes zoster and associated outcomes, Beijing, China.Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial.Incidence and risk factors of herpes zoster among adult renal transplant recipients receiving universal antiviral prophylaxis.Varicella-zoster virus susceptibility and primary healthcare consultations in Norway.Healthcare Resource Utilisation Associated with Herpes Zoster in a Prospective Cohort of Older Australian Adults.Zeroing in on zoster: A tale of many disorders produced by one virus The temporal impact of aging on the burden of herpes zoster.Extensive CD4 and CD8 T Cell Cross-Reactivity between Alphaherpesviruses.Is herpes zoster an additional complication in old age alongside comorbidity and multiple medications? Results of the post hoc analysis of the 12-month longitudinal prospective observational ARIZONA cohort study.Immunization in Canada: Update for 2015.Vaccination with the Secreted Glycoprotein G of Herpes Simplex Virus 2 Induces Protective Immunity after Genital Infection.Diversification of the antigen-specific T cell receptor repertoire after varicella zoster vaccination.Quantification of risk factors for postherpetic neuralgia in herpes zoster patients: A cohort study Potent response of QS-21 as a vaccine adjuvant in the skin when delivered with the Nanopatch, resulted in adjuvant dose sparing.Cost of Herpes Zoster in Patients With Selected Immune-Compromised Conditions in the United States.Current and future effects of varicella and herpes zoster vaccination in Germany - Insights from a mathematical model in a country with universal varicella vaccination Issues in the Treatment of Neurological Conditions Caused by Reactivation of Varicella Zoster Virus (VZV).Efficacy of varicella (VZV) vaccination: an update for the clinician.Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-Analysis.Central Role of CD169+ Lymph Node Resident Macrophages in the Adjuvanticity of the QS-21 Component of AS01.Increased risk of herpes zoster in children with cancer: A nationwide population-based cohort study.From discovery to licensure, the Adjuvant System story.Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged ≥50 years when administered subcutaneously vs. intramuscularly.Varicella zoster virus infection.Viral O-GalNAc peptide epitopes: a novel potential target in viral envelope glycoproteins.Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part II.The Neonatal Fc Receptor and Complement Fixation Facilitate Prophylactic Vaccine-Mediated Humoral Protection against Viral Infection in the Ocular Mucosa.Is chickenpox so bad, what do we know about immunity to varicella zoster virus, and what does it tell us about the future?Assessment of the potential public health impact of Herpes Zoster vaccination in Germany.The need for better preventative strategies for inflammatory bowel disease patients at risk of herpes zoster virus.

P2860

Q24186050-B5DA9886-20A5-4F8F-B619-6399D4AE4DFF Q26741484-82CDB01B-3710-4540-ABC2-C7A107EC46B3 Q26766220-A2BAACA9-FAC9-4CD9-9B2D-1B1278B8BD70 Q26778573-E71A8644-E8B0-4579-BD92-22D6A03733F3 Q26796300-EBEDA24C-77C4-49E4-8619-205973917B02 Q28079872-0B6D90C4-CFB1-4008-91B7-D541FE39FF18 Q28111717-C2D92FD0-1AB8-4FEA-9682-AB86CDDC0CFF Q30251448-12729326-CB50-417A-BAF2-1469B6C38619 Q33621700-923AD0A0-B601-454C-82DF-D7481295C49D Q33629526-2FA65364-EEF3-4958-B0B0-56E03548AE4B Q33652679-3959DFB5-B0E4-4B10-9977-AE4CE320DCDB Q33724403-4D0DCDD2-4E42-4125-BB79-CFA4C1E524E0 Q35708692-40863755-1771-4FA2-86C6-F4863B4A9687 Q36041839-E590307E-85C0-4DFE-9936-941A485BB9D4 Q36092406-6ADAE94D-2E31-4EF7-B549-7D6193FDB12D Q36236794-CF1BDAA0-6E02-4C33-B510-614AE54B1AC9 Q36257901-2E9FCB38-6912-4623-A2C8-9F784848EC12 Q36601101-39AB3D83-B1D2-4E82-8DA0-06BD91667A00 Q36602847-BADF47FC-0D71-44EE-A189-82149EA4E03B Q36728581-E5519306-0F61-41D9-ADAC-E30741BEAD9E Q36846035-C7ADE472-2BDE-4325-AEB5-18115AE6AE8A Q36931965-CA6D8452-1722-4F97-A17B-1F7035C0779F Q37063460-5BDF8BC2-8A38-4B9F-8578-60A8DDBA5478 Q37087055-AA4B4B56-4092-498E-A3EA-0A063879CD76 Q37091674-DDD4934D-9C21-49DD-9D25-09943B707AC7 Q37135445-B5058805-050B-41C3-9ABD-FA6EB397862F Q37136450-8738FB04-2F42-4407-8BE8-7E620A634576 Q37158220-6F870F88-5306-4FE5-A5D9-88396D351DF9 Q37484842-93C114D0-86E1-439D-BD46-4D056B4711EE Q37519354-86EF51B5-E494-440C-9C5B-058D42AB9E83 Q37605555-D8CB909C-CC58-426E-A748-C20A3DB1024A Q37619140-48B25C15-6C53-496F-830D-F67DE4686C7C Q37713779-B37D2278-118B-4BFE-92F5-80F1B1D48982 Q37738789-EFB29E51-215A-49CD-B111-39C09137A5FC Q38622432-F32A72B5-5F63-461D-9552-4A4AF97A3938 Q38638518-2F8C8432-B99C-4AFE-8852-11527C7F49AB Q38650844-03F66877-8440-4BD3-8042-5321C1CCE3EE Q38667215-A27AB49D-EC13-440F-942E-00C09300C0A1 Q38678770-B864BF48-BB36-4A9E-80CA-396CA40217D2 Q38682515-DFCECF98-6B58-4B7D-87DA-211ED23A7138

P2860

Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.

http://www.wikidata.org/entity/Q42145566

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.

@en

Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.

@nl

type

label

Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.

@en

Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.

@nl

prefLabel

Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.

@en

Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.

@nl

P1433

Q42145566-20893747-000E-4EA5-B9F8-9A4B2E345080

P1476

Q42145566-87A1EE4E-2562-4D1E-A35C-45293473D080

P2093

Q42145566-02840C48-CDC7-4F0C-A6EA-64F479EA067F

Q42145566-10A14BE3-D435-4370-89E4-4C6A49FAA842

Q42145566-2EF6228A-12FA-4589-BDD4-DC0C42F97761

Q42145566-35D14565-C1D0-4167-B914-003466F8D62F

Q42145566-49539C7B-04CF-495B-A604-D6D26CC0ED75

Q42145566-5EA6EF06-AAD1-44AE-B0ED-D72C61075106

Q42145566-65476FC5-53E5-4812-B105-900CA98527A6

Q42145566-7E7B398D-126D-43EA-9D50-791F08DA8343

Q42145566-81BCDCDB-9EBA-4204-9D41-7EC5E2545DC2

Q42145566-94CF300E-E244-4962-9DB1-F43178D7B313

P304

Q42145566-CAE80DF0-4789-4992-8124-041196378D85

P31

Q42145566-445D7A17-2256-4A36-86EF-DA2403AF384A

P356

Q42145566-E2E45B76-2281-48F9-8314-0DF034DB695C

P407

Q42145566-CF57D435-9148-4EA3-9F01-BEF3490387C8

P433

Q42145566-B0AD4516-AC1E-4734-96F1-B4D5B5D56A23

P478

Q42145566-E655D495-041D-48F0-BDD3-0E7068739C31

P50

Q42145566-7E834255-5EEC-4122-9B38-7CE1E7BCB0AD

P577

Q42145566-4011B2ED-F409-41EA-B4B3-4EDE38FAB829

P698

Q42145566-2177AD9A-B124-49C1-9DBE-03E4B0DC4146

P356

P1433

The New England Journal of Medicine

P1476

Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.

@en

P2093

Airi Poder

http://www.w3.org/2001/XMLSchema#string

Anthony L Cunningham

http://www.w3.org/2001/XMLSchema#string

Daisuke Watanabe

http://www.w3.org/2001/XMLSchema#string

Himal Lal

http://www.w3.org/2001/XMLSchema#string

Janet E McElhaney

http://www.w3.org/2001/XMLSchema#string

Joan Puig-Barberà

http://www.w3.org/2001/XMLSchema#string

Lily Weckx

http://www.w3.org/2001/XMLSchema#string

Myron J Levin

http://www.w3.org/2001/XMLSchema#string

Olivier Godeaux

http://www.w3.org/2001/XMLSchema#string

Roman Chlibek

http://www.w3.org/2001/XMLSchema#string

P304

2087-2096

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1501184

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

372

http://www.w3.org/2001/XMLSchema#string

P50

Javier Diez-Domingo

P577

2015-04-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25916341

http://www.w3.org/2001/XMLSchema#string